CORCEPT THERAPEUTICS (CORT) is drawing unusual attention today. Our newswire has captured 4 stories on CORT across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100).
CORT stock is down 3.51% at $92.01 in morning trading as Wolfe Research downgrades the stock to Underperform with a $50 price target. The downgrade reflects concerns over valuation, which has triggered a sharp intraday selloff after a modest rebound in recent sessions. The stock opened with a -1.8% gap and has since fallen further, reaching a session low of $90.20.
Wolfe Research issued a downgrade for Corcept Therapeutics, citing valuation concerns as the primary reason. The move comes after the company refiled its New Drug Application with the FDA for Relacorilant to treat Cushing's Syndrome, adding more data to its submission. Despite this development, the stock has struggled to hold its recent gains, with analysts focusing on the high P/E ratio of 237.2 and a market cap of $10.2 billion. The downgrade by Wolfe Research appears to have triggered immediate selling pressure, with the stock trading below its 52-week high of $97.63.
The stock opened at $93.68 and has since declined to $92.01, with volume at 0.1 million shares, which is 0.0 times the 3-month daily average. Over the last eight sessions, the stock had risen 6.5% from $89.57 to $95.36. However, the recent sell-off has erased much of that gain. Insider selling has also been notable, with 13 sales totaling $26.3 million reported in the last 90 days. The most recent insider transaction occurred on July 17, with no buys recorded in the same period.
The stock is currently trading near its 52-week low of $28.66. Investors should monitor the company’s regulatory progress with the FDA and any follow-up analyst coverage. No earnings date is scheduled in the near term.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Corcept Therapeutics (CORT) Q2 2026 earnings call: 32% revenue growth, raised $1.1B–$1.2B guidance, Lifyorli launch stats, PDUFA update—read now.
Corcept Therapeutics Incorporated (CORT) Q2 2026 Earnings Call July 29, 2026 5:00 PM EDTCompany ParticipantsAtabak Mokari - CFO & TreasurerSean Maduck -...
Filed: 2026-07-29 AccNo: 0001628280-26-050607 Size: 255 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
CORCEPT THERAPEUTICS (CORT) is drawing unusual attention today. Our newswire has captured 4 stories on CORT across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100). The most recent driver: "Corcept targets $1.1B-$1.2B 2026 revenue as Lifyorli launch reaches 1,300 patients and relacorilant awaits Dec. 17 PDUFA" (Seeking Alpha).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of CORT coverage reads 56/100 over 4 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on CORT: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier CORT move explainers: 2026-07-27 · 2026-07-23